Trisalus Life Sciences, Inc. · NASDAQ:TLSI

Trisalus Life Sciences — MedTech Acquisition — SPAC Merger (February 2023)

47 slides from Trisalus Life Sciences's SPAC merger presentation, Feb 16, 2023

Slide 2: Disclaimer
Disclaimer © 2023 TriSalus Œ Life Sciences. All Rights Reserved. 2 This presentation has been prepared by MedTech Acquisition Corporation (“ MedTech ”), formed as a special purpose acquisition company, and TriSalus Life Sciences, Inc. (“ TriSalus ”) for use in connection with a proposed business com
Slide 3: Forward-Looking Statements
Forward - Looking Statements © 2023 TriSalus Œ Life Sciences. All Rights Reserved. 3 Certain statements in this presentation may constitute “forward - looking statements” within the meaning of applicable United States federal securities laws. Forward - looking statements include, but are not limited
Slide 4: Use of Projections
Use of Projections © 2023 TriSalus Œ Life Sciences. All Rights Reserved. 4 The financial projections, estimates and targets in this presentation are forward - looking statements that are based on assumptions that are inherently subject to significant uncertainties and contingencies, many of which ar
Slide 5: Participation in Solicitation
Participation in Solicitation © 2023 TriSalus Œ Life Sciences. All Rights Reserved. 5 MedTech and TriSalus and their respective directors and executive officers, under SEC rules, may be deemed to be participants in the solicitation of proxies of MedTech’s stockholders in connection with the Proposed
Slide 6: Risk Factors
Risk Factors © 2023 TriSalus Œ Life Sciences. All Rights Reserved. 6 All r eferences to “TriSalus,” the “Company,” “we,” “us” or “our” refer to TriSalus and its consolidated subsidiaries prior to the closing of the proposed Business Combination (the “Business Combination”) with MedTech Acquisition C
Slide 7: Risk Factors (continued)
• We are subject to numerous complex regulatory requirements and failure to comply with these regulations, or the cost of compl ian ce with these regulations, may harm our business. • The complexity of a combination product that includes a drug and a medical device, presents additional, unique devel
Slide 8: Risk Factors: Legal and Regulatory Risks
Risk Factors © 2023 TriSalus Œ Life Sciences. All Rights Reserved. 8 Legal and Regulatory Risks : • There may not be an active trading market for the Combined Company Common Stock or Combined Company warrants, which may make it difficult to sell such securities. • The price of Combined Company Commo
Slide 9: TriSalus Life Sciences: Well-Positioned for Value Creation
9 TriSalus Life Sciences: Well - Positioned for Value Creation by Helping More Patients with Liver and Pancreatic Tumors Benefit From Immunotherapy Differentiated, fast - growing, commercial medtech business with potential transformational upside from a therapeutic platform focused on tumors in the
Slide 10: MTAC Team
MTAC Team Note: Certain companies under each individual are former affiliations Martin Roche, MD Director David Matlin Chief Financial Officer Chris Dewey Chief Executive Officer Karim Karti Chairman Thierry Thaure Director Manuel Aguero Director Ivan Delevic Sponsor David Treadwell Director Michael
Slide 11: The TriSalus Team
11 The TriSalus Team A Powerful Combination of Proven Clinical, Strategic and Commercial Capabilities Mats Wahlstrom Executive Chairman Mary Szela Chief Executive Officer & President Richard Marshak Senior Vice President, Business Development and Strategy Steven Katz, MD, FACS Chief Medical Officer,
Slide 12: Two Key Barriers in Treatment of Tumors in the Liver and the Pancreas
12 Two Key Barriers in Treatment of Tumors in the Liver and the Pancreas TriSalus’ Proprietary Platform is Designed to Address Both High intra - tumoral pressures limit drug delivery <1% of therapeutic may be delivered into tumor with systemic infusion 1,2 Broad immune suppression driven by Myeloid
Slide 13: TriSalus' Two-pronged, Two-solution Approach
13 TriSalus’ Two - pronged, Two - solution Approach Combining Commercial Fast - growing Device Business With a Potential Best - in - class Therapeutic Benefits of Combined Approach 3 Drug Delivery 4,5 Response Rate 4,5,6 Tolerability 4,5,6 Toxicity 6 MDSC in Liver 6,7 TriNav Infusion System SD - 101
Slide 14: Our Platform: US Annual Addressable Market Opportunity >$15B
14 Our Platform: US Annual Addressable Market Opportunity >$15B 1 • Lead indications of all areas of high unmet medical needs • Current standard of care delivers poor outcomes • High global incidence in key targeted indications provides attractive ex - US market opportunity INDICATION ANNUAL NEW CAS
Slide 16: TriNav Infusion System: A Better Solution for Drug Delivery
16 TriNav ® Infusion System: A Better Solution for Drug Delivery Commercial - stage Technology Launched in 2020 Using the Proprietary Pressure - Enabled Drug Delivery (“PEDD”) Approach • Innovative drug delivery platform designed to overcome the barriers of the high - pressure tumor microenvironment
Slide 17: Proprietary Pressure-Enabled Drug Delivery (PEDD) Technology
17 Proprietary Pressure - Enabled Drug Delivery (“PEDD”) Technology TriNav PEDD with SmartValve Technology Routine Outpatient Intravascular Regional Drug Delivery to the Liver Performed for tumors that cannot be surgically resected 4 A small puncture is made, usually into the femoral artery near the
Slide 18: PEDD Drives More Therapeutic Into High Pressure Tumors
18 PEDD Drives More Therapeutic Into High Pressure Tumors Improved Therapeutic Tumor Payload Delivery as Evidenced by Angiography and CT Angiograms Image 1: Fluoro and CT angiography via standard 5F microcatheter Image 2: Fluoro and CT angiography via TriNav Image 1: Fluoro and CT angiography via st
Slide 19: PEDD Increases Delivery of Multiple Therapeutics
19 PEDD Increases Delivery of Multiple Therapeutics Additional Clinical and Pre - clinical Data Points Support a Singular Conclusion TACE Increase in therapeutic delivery to liver tumors 1 60% TARE (y90) Increase in MAA tumor deposition in liver tumors 2 33% to 90% CAR - T Increase in CAR - T penetr
Slide 20: Strong Customer Base with Support of Key Opinion Leaders
20 Strong Customer Base with Support of Key Opinion Leaders Top TriNav Customers Select Key Opinion Leaders’ Reviews 1 “The combination of SD - 101 and the PEDD is about as exciting of a potential treatment I have seen in the IR space.” “I remain enthusiastic about the SD - 101 program, the PERIO tr
Slide 21: Reimbursement Strategy
Reimbursement Strategy Reimbursed 50% Through Private Insurance, 50% Through CMS With Action Plan Detailed Below Short - term Reimbursement 2023 Transitional Pass - through Current HCPCS Code: C1982 Current CPT Codes: 37242 – Mapping/37243 – Treatment = Current Status Long - term Reimbursement Categ
Slide 22: Pancreas Tumor Drug Delivery Approach (PRVI)
• Poor blood flow limits drug access. 1,2,3 • The pancreatic arterial system is comprised of numerous small vessels that make device access challenging. 4,5 • TriSalus developed a highly innovative and unique approach for drug delivery to pancreas tumors. • The platform is currently being investigat
Slide 23: TriSalus Technology Pipeline
TriSalus Technology Pipeline To Drive Growth of Existing Markets (Liver + Pancreas) and Potential For Creation of New Opportunities (Including Prostate) TriSalus PEDD Innovation Strategy 23 PRVI Integrated Sensing Pancreatic Retrograde Venous Infusion (PRVI) SMART DEVICE + SMART Device TriNav + Sens
Slide 25: Candidate SD-101: Class C TLR9 Agonist
25 Candidate SD - 101: Class C Toll - like Receptor 9 (TLR9) Agonist • Broad immune system reactivation within the liver and pancreas • MDSC reduction • Expected to enable deeper and more durable responses to other immunotherapeutics (e.g., checkpoint inhibitors) • Enabled by SmartValve delivery tec
Slide 26: SD-101 Dual MoA Well Suited for Liver and Pancreas Indications
26 SD - 101 Dual MoA Well Suited for Liver and Pancreas Indications Reversing Immunosuppression to Enhance Tumor Responsiveness 1,2 • Stimulates multiple immune cell types • Drives T - cell infiltration Broad Immune Modulation of the Tumor 5,6,7 1 • MDSC reduction in initial studies consistent with
Slide 27: Pressure Enabled Infusion of Immunomodulators Into Tumors
27 Pressure Enabled Infusion of Immunomodulators Directly Into the Vascular Bed of Unresponsive Liver and Pancreas Tumors Targets Dysfunctional Immune Cells in the Tumor and Organ to Enhance Checkpoint Inhibitor Performance Unresponsive Tumor TriSalus PEDD + Immunomodulator Responsive Tumor Potent I
Slide 28: SD-101 Improved Responsiveness to Anti-PD1 Therapy
28 SD - 101 Improved Responsiveness to Anti - PD1 Therapy in CPI Na ive Patients In Dynavax 1 Phase 2 for Cutaneous Melanoma Checkpoint Response Rate Increased from 35% to 78% Percent Change from Baseline, % 100 80 60 40 20 0 - 20 - 40 - 60 - 80 - 100 Unknown Positive Negative PD - L1 Status N=37 N=
Slide 29: Platform Has the Potential to Set New Immunotherapy Benchmarks
29 Platform Has the Potential to Set New Immunotherapy Benchmarks Building on Previous Phase 2 SD - 101 + CPI Data with ORR of 78% in Cutaneous Melanoma “TRANSFORMATIVE” “COMPELLING” Keytruda ® 1,2 pembrolizumab anti - PD - 1 Opdivo ® Nivolumab anti - PD - 1 Opdivo ® 1 + Yervoy ® 3 Nivolumab + Ipili
Slide 30: SD-101/PEDD Platform Milestone Anticipated Track for Clinical Trial Programs
30 SD - 101/PEDD Platform Milestone Anticipated Track for Clinical Trial Programs 2023 Q1 Q2 Q3 Q4 Uveal Melanoma 1L Liver Metastases PERIO - 1 HCC 1 2L Advanced/ Recurrent PERIO - 2 ICC 1 2L Advanced/ Recurrent PERIO - 2 PDAC 2L Locally Advanced PERIO - 3 Colorectal Cancer TBD TBD HCC/Y - 90 IIT HC
Slide 32: Studies Run by Internationally Renowned Cancer Centers
32 Studies Run by Internationally Renowned Cancer Centers Clinical Investigators Highly Enthusiastic by Approach and Data Driving Strong Enrollment – 42 Subjects Treated With 138 SD - 101 Infusions in PERIO - 01 and - 02 1 * © 2023 TriSalus Œ Life Sciences. All Rights Reserved.
Slide 33: Pipeline Designed to Enable CPI in Liver and Pancreas Tumors
33 Pipeline Designed to Enable CPI in Liver and Pancreas Tumors Platform Creates Opportunities for Orphan and Ultra - orphan Indications With Rapid Approval Potential INDICATION TRIAL DESIGN IND ENABLING PHASE 1 PHASE 2 PHASE 3 UPCOMING MILESTONES Uveal Melanoma Liver Metastases SD - 101 + PEDD HAI
Slide 34: Clinical and Pre-clinical Data Supportive of PEDD Method
34 Clinical and Pre - clinical Data 4 Supportive of PEDD Method Being Effective 1. TriSalus data on file. 2. Ghosh CC, et al. Cancer Gene Ther . 2022 Dec;29(12):1854 - 1865. 3. Reflects data obtained prior to acquisition of SD - 101. 4. Clinical Data presented as of 1/14/23 from Initial Perio - 01 a
Slide 35: Initial Data Indicate TriNav Can Achieve High Liver SD-101 Levels
35 Initial Data Indicate that TriNav ® can Achieve High Liver SD - 101 Levels with Limited Systemic Exposure © 2023 TriSalus Œ Life Sciences. All Rights Reserved. • High SD - 101 levels in liver following infusion with TriNav® • Transient (<4 hour) detection in serum following SD - 101 infusion with
Slide 36: Initial PERIO-01 and -02 Data
36 Initial PERIO - 01 and - 02 Data Subjects Treated at Lowest SD - 101 Dose Levels With ctDNA Molecular Responses to Treatment (42 Enrolled and 138 Infusions) 1 © 2023 TriSalus Œ Life Sciences. All Rights Reserved. Molecular Reponses – ctDNA clearance in majority of patients receiving SD - 101 via
Slide 37: Potential for Approval of SD-101 as Early as 2025
37 Potential for Approval of SD - 101 as Early as 2025 Orphan and Ultra - orphan Indications Offer a Potential Pathway For Expedited Development x Both ICC and uveal melanoma have potential to be designated as orphan indications which often qualify for expedited developme nt programs/review pathways
Slide 39: Interweaving Patents and Exclusivity to Increase Long Term Protection
39 Interweaving Patents and Exclusivity to Increase Long Term Protection of Intellectual Property • TriNav and SD - 101 Product - specific IP • Methods of Treatment (MoT) ― New Indications ― Combo Therapies ― Optimal Pressure Range and Dose • Platform IP ― Method optimal pressure range to overcome p
Slide 40: Patent Overview
40 Patent Overview 32 Patent Families, 119 Issued Patents, 51 Pending Applications and 2 Pending US Provisional Applications • Orphan Drug Exclusivity may provide 7 years exclusivity from approval if applied for and granted by FDA • New Chemical Entity Exclusivity may provide 5 years exclusivity fro
Slide 42: Investment Highlights
42 Investment Highlights Commercial - stage FDA cleared device with an estimated $19.2 mm sales in 2023, an estimated $42.5 mm sales in 2024, and a cash flow positive device business anticipated in 2024 Additional upside with pipeline of additional devices for liver is expected to launch in 2024 Lev
Slide 43: Go-Forward Priorities
43 Go - Forward Priorities Continue to advance PERIO Œ - 01 and PERIO Œ - 02 clinical trials to seek approval of SD - 101 Expand adoption of PEDD method Develop pipeline of additional technology devices for liver and pancreas indications © 2023 TriSalus Œ Life Sciences. All Rights Reserved. 43
Slide 44: TriSalus Has Opportunities for Significant TAM Upside
44 TriSalus Has Opportunities for Significant TAM Upside SD - 101 Annual TAM 2022A Revenue TriNav Annual TAM $12.4mm 1 $368.0mm 2 $15,000mm 3 © 2023 TriSalus Œ Life Sciences. All Rights Reserved.
Slide 45: Putting the Valuation of TriSalus into Context
Putting the Valuation of TriSalus into Context Source Capital IQ, SEC Filings. Data as of 02/14/23. Peers selected based on management’s judgement and may not be fully comp ara ble to TriSalus . Metrics based upon consensus forecasts. 1) Based on an estimated pro forma enterprise value of $238.4 mil
Slide 46: Transaction Summary
Transaction Summary ($ in millions) Cash in Trust $15.0 Private Placement of Convertible Notes 25.0 Selling Shareholder Equity Rollover 220.0 Existing TriSalus Cash Balance 1.0 Total Sources $261.0 ($ in millions) Cash on Balance Sheet $31.0 Selling Shareholder Equity Rollover 220.0 Transaction Fees

MedTech Acquisition — SPAC Merger (February 2023) on 6ix

Trisalus Life Sciences — MedTech Acquisition — SPAC Merger (February 2023)

Slide 1: February 2023 Investor Presentation

Slide 2: Disclaimer

Slide 3: Forward-Looking Statements

Slide 4: Use of Projections

Slide 5: Participation in Solicitation

Slide 6: Risk Factors

Slide 7: Risk Factors (continued)

Slide 8: Risk Factors: Legal and Regulatory Risks

Slide 9: TriSalus Life Sciences: Well-Positioned for Value Creation

Slide 10: MTAC Team

Slide 11: The TriSalus Team

Slide 12: Two Key Barriers in Treatment of Tumors in the Liver and the Pancreas

Slide 13: TriSalus' Two-pronged, Two-solution Approach

Slide 14: Our Platform: US Annual Addressable Market Opportunity >$15B

Slide 15: Fast-Growing Device Business: TriNav Infusion System

Slide 16: TriNav Infusion System: A Better Solution for Drug Delivery

Slide 17: Proprietary Pressure-Enabled Drug Delivery (PEDD) Technology

Slide 18: PEDD Drives More Therapeutic Into High Pressure Tumors

Slide 19: PEDD Increases Delivery of Multiple Therapeutics

Slide 20: Strong Customer Base with Support of Key Opinion Leaders

Slide 21: Reimbursement Strategy

Slide 22: Pancreas Tumor Drug Delivery Approach (PRVI)

Slide 23: TriSalus Technology Pipeline

Slide 24: Significant Potential Upside from SD-101 Program in Development

Slide 25: Candidate SD-101: Class C TLR9 Agonist

Slide 26: SD-101 Dual MoA Well Suited for Liver and Pancreas Indications

Slide 27: Pressure Enabled Infusion of Immunomodulators Into Tumors

Slide 28: SD-101 Improved Responsiveness to Anti-PD1 Therapy

Slide 29: Platform Has the Potential to Set New Immunotherapy Benchmarks

Slide 30: SD-101/PEDD Platform Milestone Anticipated Track for Clinical Trial Programs

Slide 31: Pressure-Enabled Regional Immuno-Oncology Studies

Slide 32: Studies Run by Internationally Renowned Cancer Centers

Slide 33: Pipeline Designed to Enable CPI in Liver and Pancreas Tumors

Slide 34: Clinical and Pre-clinical Data Supportive of PEDD Method

Slide 35: Initial Data Indicate TriNav Can Achieve High Liver SD-101 Levels

Slide 36: Initial PERIO-01 and -02 Data

Slide 37: Potential for Approval of SD-101 as Early as 2025

Slide 38: Extensive Patent Protection Position

Slide 39: Interweaving Patents and Exclusivity to Increase Long Term Protection

Slide 40: Patent Overview

Slide 41: Investment Opportunity

Slide 42: Investment Highlights

Slide 43: Go-Forward Priorities

Slide 44: TriSalus Has Opportunities for Significant TAM Upside

Slide 45: Putting the Valuation of TriSalus into Context

Slide 46: Transaction Summary

Slide 47: Thank You